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Abstract 
Atherosclerosis commences with the trapping of low density lipoproteins (LDLs) in 
blood vessels by modified proteoglycans (PGs) with hyperelongated glycosaminoglycan 
(GAG) chains. GAG chain synthesis and growth factor mediated hyperelongation regulates 
the composition and size of PGs in a manner that would cause low density lipoprotein 
(LDLs) retention in vessel wall. Galactosaminoglycans are a class of GAGs, commonly 
observed on PGs. Multiple enzymes are involved in galactosaminoglycan biosynthesis. 
Galactosaminoglycan synthesis is regulated by various signalling pathways which are 
amenable to pharmacological manipulation to treat atherosclerosis. Receptor mediated 
signalling pathways including protein tyrosine kinase receptors (PTKRs), serine/threonine 
kinase receptors (S/TKRs) and G-protein coupled receptors (GPCRs) pathways regulate 
galactosaminoglycan synthesizing enzyme expression. Increased expression of these enzymes 
modify galactosaminoglycan chain structure by making them hyperelongated. This review 
focuses on the signalling pathways regulating the expression of genes involved in 
galactosaminoglycan synthesis and modification. Furthemore, there are multiple other 
processes for inhibiting the interactions between LDL and galactosaminoglycans such as 
peptide mimetics of ApoB100 and anti-galactosaminoglycan antibodies and the therapeutic 
potential of these strategies is also addressed.  
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Abbreviations 
Ang-II, Angiotensin-II  
CDKs, Cyclin-dependent kinases  
ChGn, Chondroitin N-acetylgalactosaminyltransferase 
ChPF, Chondroitin polymerizing factor 
ChSy, Chondroitin synthase 
CS, Chondroitin sulfate 
CVDs, Cardiovascular diseases 
C4S, Chondroitin-4-sulfate  
C6S, Chondroitin-6-sulfate  
C4ST, Chondroitin 4-O-sulfotranferase 
C6ST, Chondroitin 6-O-sulfotranferase 
DS,  Dermatan sulfate 
DSE, Dermatan sulfate epimerase 
D4ST, Dermatan 4-O-sulfotranferase 
EGF, Epidermal growth factor 
EGFR, Epidermal growth factor receptor 
Erk1/2, Extracellular signal-regulated kinase 1/2  
ET-1, Endothelin-1  
GAGs, Glycosaminoglycans 
Gal, Galactose 
GalT, β-1,3-galactosyl transferase 
GalNAc, N-acetyl-D-galactosamine  
GalNAcT, N-acetylgalactosyl transferase 
GalNAc4S-6ST, N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase 
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GlcA, Glucuronic acid 
GlcNAc, N-acetyl-D-glucosamine 
GlcAT, β-1,3-glucuronosyl transferase 
GPCR, G-protein coupled receptors  
HMGCoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A 
IdoA, Iduronic acid 
IP3, Inositol 1,4,5 triphosphate  
LDLs, Low density lipoproteins  
mAb, Monoclonal antibody 
MMPs, Matrix metalloproteinases  
PCSK9, Proprotein convertase subtilisin/kexin type 9 
PDGF, Platelet derived growth factor  
PDGFR, Platelet derived growth factor receptor 
PGs, Proteoglycans  
PI3K, Phosphoinositide 3-kinase  
PKC, Protein kinase C  
PLC, Phospholipase C  
PTKRs, Protein tyrosine kinase receptors 
Ser, Serine 
Sos, Son of sevenless  
S/TKRs, Serine/threonine kinase receptors  
TGF-β, Transforming growth factor-β  
TGFBR, Transforming growth factor-β receptor 
Thr, Threonine 
Tyr, Tyrosine 
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UST, Uronosyl 2-O-sulfotranferase 
VSMCs, Vascular smooth muscle cells  
Xyl, Xylose 
XT, Xylosyltransferase 
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1. Introduction 
Cardiovascular diseases (CVDs) are a heterogeneous group of conditions afflicting heart 
and blood vessels which share common underlying pathological mechanisms 
(Aghamohammadzadeh, Ormandy, & Heagerty, 2015). CVDs are the largest single cause of 
death globally and more people die annually from CVDs than from any other cause (Mendis, 
Puska, & Norrving, 2011; WHO, 2017). Atherosclerosis is a progressive disease 
characterized by lipid accumulation in the large arteries and it constitutes the single most 
important contributor to this enormous burden of disease and it is accelerated in the presence 
of diabetes (Libby, 2002; Nigro, Osman, Dart, & Little, 2006; Yang, et al., 2010). 
Atherosclerosis commences with the pre-inflammatory stage occurring as accumulation of 
lipids in the blood vessel wall followed by an inflammatory stage which is manifest 
ultimately as the formation of atherosclerotic plaques (Libby, 2002; Ross, 1999; Virmani, et 
al., 2005).  Plaques may be stable or unstable with plaque rupture, causing the acute clinical 
syndrome of a life threatening myocardial infarction or stroke (Davies, 1996; Falk, 1989). 
The major pathological mechanisms currently under investigation as causes of atherosclerosis 
are the retention of low density lipoproteins (LDLs) (Skalen, et al., 2002), endothelial 
dysfunction (Davignon & Ganz, 2004), oxidative stress (Witztum, 1994), inflammation 
(Libby, 2002; Ross, 1999) and immune system defects (Fernández-Ruiz, 2016; Little, Chait, 
& Bobik, 2011).  In human coronary arteries, atherosclerosis commences with the retention 
of LDLs by galactosaminoglycans on proteoglycans (PGs), specifically biglycan and this is 
followed by the immune response and the inflammatory cascade (Nakashima, Fujii, 
Sumiyoshi, Wight, & Sueishi, 2007). Utilization of genetically modified apolipoprotein 
knockout mice demonstrates the primary role of LDLs and PGs in atherogenesis (Skalen, et 
al., 2002). Boren et al. (Kijani, Vázquez, Levin, Borén, & Fogelstrand, 2017) confirmed that, 
vascular LDL retention is almost exclusively dependent on electrostatic interactions between 
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galactosaminoglycans and LDLs. In a murine model of atherosclerosis, the increased 
expression of galactosaminoglycan synthesizing genes is associated with lipid accumulation 
in the vessel wall (Anggraeni, et al., 2011).  
In early atherogenesis, negatively charged sulfate and carboxyl groups of 
galactosaminoglycan chains on PGs in the extracellular matrix of the arterial intima bind and 
trap LDLs via electrostatic interactions with positively charged aminoacyl residues in the 
apoB moiety of an LDL particle (Borén & Williams, 2016; Ohira & Iso, 2013). LDL particles 
normally flux into and out of the arterial wall, most LDL particles that enter the arterial wall 
leave without contributing to the development of the atherosclerotic lesion (Borén & 
Williams, 2016; Schwenke & Carew, 1989; Tran-Lundmark, et al., 2008). LDL particles 
become trapped in the vessel wall because of the changes in the properties of both the LDLs 
and the extracellular matrix, particularly galactosaminoglycan chains on PGs (Haberland, 
Olch, & Folgelman, 1984; Little, Osman, & O'Brien, 2008; Nakashima, et al., 2007; Tabas, 
1999). 
Multiple signalling pathways are involved in regulating galactosaminoglycan 
synthesizing enzyme gene expression, which direct structural changes in 
galactosaminoglycan chains on PGs and increase their binding affinity to LDLs in the vessel 
wall. These signalling pathways represent potential targets for therapeutic intervention of 
atherosclerosis and thus are the subject of the current review. 
 
2. Galactosaminoglycan structure contributes to LDL binding  
2.1 Strucutural features of galactosaminoglycans  
The major glycosaminoglycans (GAGs) in vertebrates include glucosaminoglycans 
(heparan sulfate (HS), keratan sulfate (KS), heparin (Hep)) and galactosaminoglycans 
(chondroitin sulfate (CS) and dermatan sulfate (DS)) (Kjellén & Lindahl, 1991). The GAG 
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chains are composed of alternating units of an amino sugar, either N-acetyl-D-glucosamine 
(GlcNAc) or N-acetyl-D-galactosamine (GalNAc) and a hexauronic acid either glucuronic 
acid (GlcA) or iduronic acid (IdoA). The presence of either type of amino sugar differentiates 
between glucosaminoglycans and galactosaminoglycans. GlcNAc or GalNAc is found to be 
present in disaccharide units of glucosaminoglycans and galactosaminoglycans, respectively. 
Although the polysaccharide backbones are simple, linear chains of repetiting disaccharide 
units, Hep/HS and CS/DS acquire a considerable degree of structural variability by extensive 
modifications involving sulfation and uronic acid epimerization (Kjellén & Lindahl, 1991; 
Yamada, Sugahara, & Özbek, 2011).  
 Galactosaminoglycan chains on PGs are complex, long, unbranched polysaccharides 
with important roles in cell growth, differentiation, morphogenesis, cell migration and 
microbial infection (Yamada, et al., 2011). Galactosaminoglycan chains are covalently 
attached to the core protein to form PGs, which are ubiquitously distributed in the 
extracellular matrix (Kjellén & Lindahl, 1991). Particularly, galactosaminoglycan chains are 
attached to a serine (Ser) residue on the core protein through the common linkage region 
tetrasaccharide, which is made up of xylose-galactose-galactose-glucuronic acid 
(Xyl-Gal-Gal-GlcA) (Fig 1). The galactosaminoglycan chains are generated principally by 
similar modifications to glucosaminoglycans with an initial polymerization product of the 
disaccharide unit GlcA/IdoA-GalNAc. The structural diversity of galactosaminoglycans is 
less pronounced than heparin related species as the GalNAc residues remain acetylated 
(Kjellén & Lindahl, 1991). The range of normal galactosaminoglycan chain lengths vary 
widely and extends from 20 kDa to approximately 60 kDa corresponding to approximately 40 
to 120 disaccharides (Little, Ballinger, Burch, & Osman, 2008). Epimerization at the 
carbon-5 (C-5) position of GlcA in precursor chondroitin backbone results in the formation of 
repeating disaccharide unit GalNC-IdoA or dermatan backbone (A Malmström & Fransson, 
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1975). Both CS and DS galactosaminoglycans are fully developed through sulfation by the 
action of sulfotransferases. Galactosaminoglycans are mainly sulfated at C-4 and C-6 
positions of their GalNAc moieties. C-2 and C-3 positions of GlcA and IdoA are other 
positions available for sulfation of galactosaminoglycan chains and therefore various types of 
di and trisulfated disachharide units may form (Karamanos, Syrokou, Vanky, Nurminen, & 
Hjerpe, 1994). 
2.2 Galactosaminoglycan structure and LDL binding  
There are three major structural properties of galactosaminoglycans that are regulated by 
signalling pathways and can influence their binding to apolipoproteins on LDLs. These 
include modification in the length of the chains (number of disaccharide units), the extent and 
pattern of sulfation and the isoform of the uronic acid moiety on the galactosaminoglycan 
chain (Ballinger, Nigro, Frontanilla, Dart, & Little, 2004). Treatment of VSMCs with 
multiple vascular agonists stimulates cells to produce elongated galactosaminoglycan chains 
which is associated with an increased binding to LDL (Figueroa & Vijayagopal, 2002; 
Getachew, Ballinger, Burch, Reid, et al., 2010). In aortic smooth muscle cells, oxidized LDL 
causes biglycan galactosaminoglycan chain elongation with increased LDL binding (Chang, 
Potter-Perigo, Tsoi, Chait, & Wight, 2000). Comparative studies with CS and DS PGs 
indicate that DS PGs are more efficient at LDL binding. Oversulfation is considered as the 
prime feature involved in increased LDL binding to DS molecules (Sambandam, Baker, 
Christner, & Ekborg, 1991). Both the degree of sulfation and the position of the sulfate 
groups on the galactosaminoglycans, determines their binding ability to LDLs (Ballinger, et 
al., 2004; Sambandam, et al., 1991). In early atherosclerosis, the ratio of 
deltadi-mono-6-sulfate/deltadi-mono-4-sulfate (Δdi-mono6S/Δdi-mono4S) in 
galactosaminoglycan chains is increased which reflects the similar increase in the ratio of 
CS/DS, since CS is mainly composed of C-6 sulfated disaccharides, whereas DS is mainly 
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composed of C-4 sulfated units (Theocharis, Theocharis, De Luca, Hjerpe, & Karamanos, 
2002). These changes may facilitate the LDL accumulation in the aortic wall. Similar pattern 
of increases in C-6 sulfation (6S)/4S of galactosaminoglycan chains in the aorta of rats fed a 
high cholesterol diet have also been reported (Oberkersch, et al., 2014). Enzymatic 
epimerization of the carboxylic acid group on the C-5 position of the GlcA generates the 
isomer IdoA, by definition, the galactosaminoglycan chain changes from CS to DS. These 
two molecules show different levels of structural flexibility and rigidity that determine LDL 
binding. GlcA exists in a single well defined chair conformation, on the other hand IdoA 
residues exist in multiple isoenergetic conformers. IdoA containing galactosaminoglycan 
chains bind more avidly to LDL than GlcA containing galactosaminoglycans (Gigli, Ghiselli, 
Torri, Naggi, & Rizzo, 1993). Although the overall charge densities of the molecules are 
similar, IdoA containing galactosaminoglycans exhibit local concentrations of charge for 
ionic binding of galactosaminoglycan to the apolipoprotein on LDLs (Iverius, 1972).  
Animal models of atherosclerosis have provided strong evidence to support the role of 
galactosaminoglycan in lipid binding and atherosclerotic lesion development (L Delgado-
Roche, et al., 2013; Livan Delgado-Roche, et al., 2015; Sarduy, et al., 2017 ). Mice 
immunized with chimeric mouse/human antibodies against galactosaminoglycans and fed a 
high-fat, high cholesterol diet showed a 40% reduction in aortic lesion area due to inhibition 
of LDL-CS binding and reduction of oxidative stress (Víctor Brito, et al., 2012). 
3. Enzymes involved in galactosaminoglycan biosynthesis and modification 
Biosynthesis of galactosaminoglycan chains on PGs involves the concerted action of 
multiple enzymes (Fig 1). The initiation of the linkage region requires the 
xylosyltransferase-1 (XT-1) enzyme, to transfer a Xyl to Ser residue of PG core protein 
(Götting, Kuhn, & Kleesiek, 2007). Subsequently, the combined action of three enzymes 
β-1,3-galactosyl transferase-1 (GalT-1), GalT-2 and β-1,3-glucuronosyl transferase-1 
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(GlcAT-1) add two Gal and one GlcA residues to form the linkage region (Uyama, Kitagawa, 
& Sugahara, 2007). This linkage region connects the galactosaminoglycan chain to the core 
protein. Polymerization of repeating disaccharide units (GalNAc-GlcA) in CS chains occurs 
by the action of six chondroitin synthase enzymes including chondroitin synthase-1 (ChSy-1), 
ChSy-2, ChSy-3, chondroitin polymerizing factor (ChPF), chondroitin 
N-acetylgalactosaminyltransferase-1 (ChGn-1) and ChGn-2 (Izumikawa, et al., 2008; 
Izumikawa, Uyama, Okuura, Sugahara, & Kitagawa, 2007). The precursor CS backbone is 
matured and modified by sulfation with the action of a number of enzymes including 
uronosyl 2-O-sulfotranferase (UST), chondroitin 4-O-sulfotranferase (C4ST), chondroitin 
6-O-sulfotranferase (C6ST) (Uyama, et al., 2007). CS backbone is modified to the DS with 
the epimerization action of the DS epimerase (DSE) enzyme at C-5 position of GlcA in CS 
backbone. DS backbone is fully matured by sulfation with the action of a different set of 
sulfotransferases, UST and dermatan 4-O-sulfotranferase (D4ST) (Evers, Xia, Kang, 
Schachner, & Baenziger, 2001). An enzyme N-acetylgalactosamine 4-sulfate 
6-O-sulfotransferase (GalNAc4S-6ST) transfers sulfate to the C-6 position of 
N-acetylgalactosamine 4-sulfate (GalNac(4SO4)) in both growing CS and DS chains (Ohtake, 
Ito, Fukuta, & Habuchi, 2001). All these sulfotranferases (regardless CS and/or DS) transfer 
sulfate groups to the different corresponding positions of GlcA and IdoA (Anders 
Malmström, Bartolini, Thelin, Pacheco, & Maccarana, 2012; Uyama, et al., 2007). ChSy-1 
and ChSy-2 are bifunctional glycosyltransferases that exhibit GlcAT-2 and 
N-acetylgalactosyl transferase-2 (GalNAcT-2) activity (Izumikawa, et al., 2008; Izumikawa, 
et al., 2007). ChSy-3 exhibits only GlcAT activity (Izumikawa, et al., 2008). Whereas 
ChSy-1 and ChSy-2 are responsible for CS chain elongation, ChGn-1 and ChGn-2 catalyse 
both the chain initiation and elongation (Sato, et al., 2003).  ChGn-1 and ChGn-2 enzymes 
exhibit GalNAcT-1 and GalNAcT-2 activity (Gotoh, et al., 2002; Sato, et al., 2003). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 14 / 46 14/02/2018 
Chondroitin polymerization can be achieved by the combined action of enzyme complexes 
composed of any of two ChSys and ChPF (Izumikawa, et al., 2008; Izumikawa, et al., 2007). 
This enzyme complexes with chondroitin polymerase activity and interacts with C4ST-1 to 
regulate the length of CS chains (Izumikawa, Okuura, Koike, Sakoda, & Kitagawa, 2011).  
ChGn-1 regulates the chain numbers and level of CS and  co-operates with C4ST-2 to 
increase the number of CS moieties (Izumikawa, Koike, & Kitagawa, 2012). Therefore, 
biosynthesis and chain length of galactosaminoglycans are not only regulated by chondroitin 
synthase family members but also CS sulfotranferases. Although an array of enzymes is 
involved in galactosaminoglycan chain elongation, ChGn-2 and C4ST-1 play a critical role in 
the regulation of galactosaminoglycan chain length in vitro (Izumikawa, et al., 2011). An 
increase in the CS/DS synthesis was found in a atherosclerotic mouse model study 
accompanied by an increased expression of these two enzymes (Anggraeni, et al., 2011). 
Thus the critical role of ChGn-2 and C4ST-1 in galactosaminoglycan chain elongation 
regulation was demonstrated both in vivo and in vitro.  
4. Signalling pathways regulating galactosaminoglycan synthesis and structure 
4.1 Protein tyrosine kinase receptor (PTKR) pathways 
The PTKRs are transmembrane glycoproteins that are activated by the binding of their 
ligands (Hubbard & Till, 2000). PTKRs are involved in activation of numerous signalling 
pathways leading to cell proliferation, differentiation, migration or metabolic changes 
(Schlessinger, 2000). The PTKR family includes insulin receptors and numerous growth 
factor receptors such as platelet derived growth factor (PDGF), epidermal growth factor 
(EGF), fibroblast growth factor, vascular endothelial growth factor and nerve growth factor 
(Hubbard & Till, 2000). Growth factors such as PDGF and EGF are involved in the 
hyperelongation of galactosaminoglycan chains by altering gene expression utilizing  
classical PTKR signaling (Getachew, Ballinger, Burch, Reid, et al., 2010; Yang, et al., 2009).  
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PDGF via its cognate receptor stimulates  the elongation of galactosaminoglycan 
chains on PGs  (Getachew, Ballinger, Burch, Reid, et al., 2010; Schonherr, Jarvelainen, 
Kinsella, Sandell, & Wight, 1993). In human VSMCs PDGF stimulates autophosphorylation 
and activation of the PDGFRα and PDGFRβ in their kinase activation domain tyrosine849 
(Tyr
849
)
 
and Tyr
857
, respectively (Getachew, Ballinger, Burch, Reid, et al., 2010). Imatinib, a 
small molecule tyrosine kinase inhibitor blocks PDGFRβ by inhibiting autophosphorylation 
on Tyr
857
, thus inhibiting galactosaminoglycan hyperelongation and LDL retention 
(Ballinger, et al., 2010). Tyrosine kinase inhibitor, Ki11502 blocks Tyr
857
 
autophosphorylation on PDGFRβ, and is more potent than imatinib in inhibiting 
galactosaminoglycan elongation (Getachew, Ballinger, Burch, Little, & Osman, 2010). In 
contrast, genistein, a tyrosine kinase inhibitor does not block PDGFR autophosphorylation. 
Genistein inhibits PG core protein synthesis but has no effect on galactosaminoglycan chain 
elongation in VSMCs (Little, et al., 2012). These studies demonstrated that PDGFRβ 
autophosphorylation in Tyr
857
 is crucial to PDGF stimulated galactosaminoglycan chain 
elongation. PDGF also stimulates phosphorylation in  Tyr
751
 and Tyr
1021 
on PDGFR, these are 
associated with downstream signalling via phosphoinositide 3-kinase (PI3K) and 
phospholipase C (PLC). Although neither of these sites mediate galactosaminoglycan 
elongation however both sites are associated with increased PG core protein synthesis 
(Getachew, Ballinger, Burch, Reid, et al., 2010).  
Phosphorylation of PDGFRβ Tyr857 initiates extensive autophosphorylation of 11 Tyr 
residues within the cytoplasmic region of the receptor. These sites serve as tyrosine kinase 
docking sites for  a number of adaptor molecules containing SH2 domains such as Grb and 
Shc. For instance, Grb and Shc can bind to Tyr
740
 and Tyr
771
,
 
respectively on PDGFRβ. These 
molecules form complexes with son of sevenless (Sos), a guanine nucleotide exchange factor 
to activate Ras (Heldin & Westermark, 1999). Activated Ras sequentially  activates 
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extracellular signal-regulated kinase 1/2 (Erk1/2) through the Ras/Raf/MEK/Erk pathway. 
Erk1/2 is associated with galactosaminoglycan elongation in VSMCs (Getachew, Ballinger, 
Burch, Reid, et al., 2010). Transcription factor Sp1  is phosphorylated by Erk1/2 on 
threonine
453
 (Thr
453
) (Tan & Khachigian, 2009). PDGF treatment in VSMCs, produced peak 
of Thr
453 
Sp1 phosphorylation which is blocked in the presence of Erk inhibitors. This 
suggests the possible role of the Sp1 in galactosaminoglycan chain elongation (Getachew, 
Ballinger, Burch, Reid, et al., 2010). Barre et al. (Barré, et al., 2006) demonstrated that Sp1 
phosphorylated and activated by Erk1/2 is a transactivator of GlcAT-1 gene promoter leading 
to increased expression of the GlcAT-1 enzyme in HeLa cells. In a recent study, ChSy-1 
expression was found to be induced by Erk1/2 activated Sp1 in rat nucleus pulposus cells 
(Hu, et al., 2015). Together these results indicate an involvement of Sp1 in PDGF stimulated 
expression of CS enzymes and subsequent hyperelongation of CS chains (Fig 2).  
PDGF leads to modifications in the sulfation pattern of CS chains. An increase in the 
the chondroitin-6-sulfate (C6S) to chondroitin-4-sulfate (C4S)  ratio was found in PDGF 
treated monkey arterial smooth muscle cells. PDGF utilizes protein kinase C (PKC) signaling 
leading to the activation Ras/Raf/MEK/Erk pathway to mediate the changes in sulfation 
pattern of CS chains, but PKC activity alone is insufficient to generate this response 
(Cardoso, et al., 2010). The serine/threonine kinase, Akt is found to be phosphorylated in 
response to PDGF stimulation. Akt phosphorylation is associated with PG core protein 
synthesis but it has no effect on PTKR stimulated galactosaminoglycan elongation or the 
expression of C4ST-1 gene (Osman, et al., 2014). Another PTKR, EGF receptor (EGFR) 
stimulates the mRNA expression of galactosaminoglycan synthesizing gene ChSy-1 and 
C4ST-1 via downstream signaling intermediate Erk1/2, which is inhibited by EGFR 
antagonists AG1478 in VSMCs (Kamato, et al., 2016). PTKR mediated signaling pathways 
in response to their agonist stimulation are directly involved in inducing expression of 
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galactosaminoglycan synthesizing genes leading to the synthesis of hyperelongated 
galactosaminoglycan chains. These hyperelongated galactosaminoglycan chains render the 
vessel wall “more sticky” to trap more LDLs and initiates the pre-inflammatory stage of 
atherosclerosis.  
4.2 Serine/threonine kinase receptors (S/TKRs) pathways 
A family of transmembrane receptors that contain intracellular serine/threonine kinase 
domain is known as S/TKRs and ligands of these receptors include TGF-β superfamily 
members such as TGF-β, activin, nodal and others (ten Dijke, et al., 1994). TGF-β is a 
pleiotropic growth factor associated with the development of all stages of atherosclerosis. 
TGF-β family members consist of dimeric ligands and usually remain in a latent form bound 
to their polypeptide. When released from their polypeptide, these ligands become active and 
bind to dimers of membrane TGF-β receptors (TGFBRs). Following ligand binding, 
TGFBR1 dimers combine with TGFBR2 dimers to form heterotetrameric receptor 
complexes. Phosphorylation of TGFBR1 by TGFBR2 leads to the formation of active 
heterotetrameric receptor complexes (Massague, Seoane, & Wotton, 2005).  
TGF- has a very specific action on galactosaminoglycan elongation and has no 
effects on the C6S to C4S ratio (Schonherr, et al., 1993). Transcription factor Smad2 is an 
immediate downstream target of TGFBR1 in the TGF-β stimulated signalling pathway. 
Smad2 consists of an amino-terminal or “Mad-homology 1” (MH1) domain, a linker region 
and a carboxy-terminal or MH2 domain (Massague, et al., 2005). The canonical TGF-β 
signalling pathway via the TGFBR1 involves the phosphorylation of the Smad2 
carboxy-terminal, which forms a complex with Smad4 to translocate to the nucleus (Burch, 
Zheng, & Little, 2011; Derynck, Zhang, & Feng, 1998; Massague, et al., 2005). In addition to 
carboxy terminal phosphorylation, the Smad2 linker region can undergo phosphorylation on 
Thr
220
, Ser
245
, Ser
250
, Ser
255
 residues (Kamato, et al., 2014; Rostam, et al., 2016). Smad linker 
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region phosphorylation can occur by multiple serine/threonine kinases such as MAP kinases 
(Erk and p38), PI3K, cyclin-dependent kinases (CDKs), Rho associated protein kinase 
(ROCK) and glycogen synthase kinase 3 (GSK3) (Burch, Yang, et al., 2010; Kamato, Burch, 
Piva, et al., 2013; Matsuzaki, 2013; Rezaei, Kamato, Ansari, Osman, & Little, 2012). Highly 
specific signalling pathways from TGF-β to Smad2 linker region phosphorylation exist in 
human VSMCs (Rostam, et al., 2016). Serine/threonine kinases Erk, p38, PI3K and CDK 
mediate the phosphorylation of the Ser
245
/Ser
250
/Ser
255
 residues whereas only CDK is found 
to phosphorylate the Thr
220
 residue in Smad2 linker region. Phosphorylation of three Ser 
residues (Ser
245
, Ser
250
 and Ser
255
) in Smad2 linker region induces expression of two 
galactosaminolycan synthesizing enzymes ChSy-1 and C4ST-1, however phosphorylation of 
Thr
220
 is associated with induction of XT-1, the enzyme involved in the initiation of the 
galactosaminoglycan linkage region (Rostam, et al., 2016) (Fig 3). Phosphorylation of any of 
the three Ser residues on Smad2 linker region is involved in galactosaminoglycan chain 
elongation. In contrast, Thr
220
 phosphorylation on Smad2 linker region can induce 
galactosaminoglycan chain initiation. XT-1 expression is up-regulated by TGFβ1 in cardiac 
fibroblasts with a corresponding increased synthesis of galactosaminoglycans in cardiac 
tissues. A specific knock-down of the XT-1 mRNA with siRNA resulted in a decreased XT-1 
activity and lower galactosaminoglycan synthesis in vivo (Prante, et al., 2007). 
 S/TKR signalling pathways play a crucial role in galactosaminoglycan synthesizing 
enzyme expression via Smad2 linker region phosphorylation. TGF-β stimulated 
overexpression of these genes involved in both galactosaminoglycan chain initiation and 
elongation render the vessel wall more susceptible to LDL binding.   
4.3 G-protein coupled receptors (GPCRs) pathways 
Seven transmembrane GPCRs are the most prolific and polyfunctional group of cell 
surface receptors in mammalian biology and are heavily implicated in physiology and 
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pathology. These receptors are coupled to G proteins with α, β and γ subunits which act as 
effectors of GPCR signalling (Pierce, Premont, & Lefkowitz, 2002). Downstream mediators 
of GPCR signaling include inositol 1,4,5 triphosphate (IP3) leading to the increased cytosolic 
calcium and activation of protein kinase C (PKC) (Gilman, 1987).  
Vasoactive GPCR agonists endothelin-1 (ET-1) (Little, Burch, Getachew, Al-aryahi, 
& Osman, 2010), angiotensin-II (Ang-II) (Figueroa & Vijayagopal, 2002) and thrombin 
(Burch, Ballinger, et al., 2010) stimulate PG synthesis in VSMCs. ET-1 stimulates PG 
synthesis with longer galactosaminoglycan chains and increased C6S to C4S ratio (Ballinger, 
Ivey, Osman, Thomas, & Little, 2009). Ang-II induces an increase in PG synthesis in human 
thoracic aorta smooth muscle cells, which is due to galactosaminoglycan chain 
hyperelongation and increased sulfation (Figueroa & Vijayagopal, 2002). Previous studies 
targeted the involvement of classical GPCR signaling pathways in PG synthesis and 
galactosaminoglycan chain elongation (Burch, Ballinger, et al., 2010; Survase, Ivey, Nigro, 
Osman, & Little, 2005). IP3 and cytosolic calcium ions do not effect PG synthesis in VSMCs 
(Burch, Ballinger, et al., 2010; Survase, et al., 2005). Although, PKC can play an important 
role in PG synthesis and galactosaminoglycan chain elongation (Cardoso, et al., 2010). GPCR 
agonists do not stimulate PG synthesis and galactosaminoglycan chain elongation via 
classical GPCR mediated signalling pathways. 
GPCRs can transactivate both PTKRs (Daub, Weiss, Wallasch, & Ullrich, 1996) and 
S/TKRs (Burch, Ballinger, et al., 2010; Kamato, et al., 2017; Kamato, Burch, Osman, Zheng, 
& Little, 2013). Indeed, the recognition of  the ability of GPCRs to transactivate PTKRs and 
S/TKRs was discovered in the context of galactosaminoglycan chain elongation (Kamato, et 
al., 2016). Thrombin can stimulate PG synthesis in VSMCs which utilizes both PTKRs and 
S/TKRs transactivation pathways (Burch, Getachew, Osman, Febbraio, & Little, 2013). 
Thrombin elicits dual transactivation-dependent signaling pathways to stimulate ChSy-1 and 
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C4ST-1 mRNA expression (Kamato, et al., 2016) (Fig 4). Thrombin stimulation of 
galactosaminoglycan synthesizing enzyme expression occurs entirely via 
transactivation-dependent pathways and conversely does not involve 
transactivation-independent pathways (Kamato, et al., 2015). The transactivation of PTKR 
involves matrix metalloproteinases (MMPs) and the phosphorylation of Erk. In contrast, the 
S/TKR mediated response involves phosphorylation of Ser residues on Smad2 carboxy 
terminal and does not inolve MMPs. Chung et al. (Chung, Ramachandran, Hollenberg, & 
Muruve, 2013) showed  similar results with TGFBR1 transactivation by proteinase-activated 
receptor-2 (PAR-2), except transactivation of TGFBR1 was reported to be dependent on 
MMPs. Smad2 linker region phosphorylation via thrombin stimulation is inhibited by the 
MMP inhibitor, GM6001 (Kamato, et al., 2016). MMPs are involved in GPCR 
transactivation of EGFR but not TGFBR1. Therefore, thrombin mediated Smad2 linker 
region phosphorylation occurs possibly via GPCR transactivation of PTKR not GPCR 
transactivation of S/TKRs. Smad2 linker region phosphorylation is of considerable interest 
because identifying a common target molecule downstream to distinct receptor mediated 
signaling pathways for the regulation of PG synthesis and galactosaminoglycan 
hyperelongation would be a potential therapeutic target for the prevention of atherosclerosis. 
5. Potential of the response to retention hypothesis for providing a therapeutic agent for 
the prevention or treatment of atherosclerosis 
The response to retention hypothesis proposes that atherosclerosis commences with the 
entry, binding and trapping of atherogenic LDLs by modified PGs in the vessel wall. So what 
are the potential therapeutic modalities to exploiting this hypothesis therapeutically? 
5.1 Lowering plasma LDL cholesterol 
LDL cholesterol lowering is the current gold standard and recommended treatment for 
preventing atherosclerosis. Simply lowering plasma cholesterol should reduce the cholesterol 
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flux into the vessel wall. Statins were consistently successful in multiple clinical trials and 
have been very successful in reducing CVD risk and events in real world therapeutic use for 
over two decades. There are multiple statins available and their actions and outcomes have 
been extensively reviewed (Collins, et al., 2016; Ehrenstein, Jury, & Mauri, 2005; Taylor, et 
al., 2013). 
More recently proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors have been 
developed – these agents bind to PCSK9 preventing its action in degrading LDL receptors 
leading to major upregulation of LDL receptors and an increased uptake of cholesterol and 
lowered plasma cholesterol (Yadav, Sharma, & Ferdinand, 2016). With statins expressing 
such high efficacy the rationale for PCSK9 inhibitors is less than clear. Both statins and 
PCSK9 inhibitors cause mild hyperglycaemia meaning an increase in diabetes depending 
upon the starting glycaemia status and susceptibility of the patient cohort (Schmidt, et al., 
2017; Shah & Goldfine, 2012).  
The efficacy of statins in preventing CVD is such that some clinical guidelines 
(Lloyd-Jones, Goff, & Stone, 2014) even indicate the use of a statin without ongoing 
reference to the plasma cholesterol level. This is related to the demonstrated clinical efficacy 
but also at least in part the wide range of favourable, pleiotropic, cardiovascular protective 
actions which have been demonstrated for statins (Collins, et al., 2016; Ford, Murray, 
McCowan, & Packard, 2016; Taylor, et al., 2013). Importantly, in the current context, statins 
have no effects on PG synthesis in VSMCs (Little and Osman, unpublished observations) so 
such an action is not in the group of anti-inflammatory, anti-oxidation and other actions 
which add to the cholesterol lowering actions of statins and thus targeting PG-LDL 
interactions is a bona fide approach in combination with a statin. 
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5.2 Targeting the interaction between LDLs and PGs 
5.2.1 Small peptide mimetics of ApoB100 
One potential mechanism to block the interaction between amino acids on ApoB100 
and sulfate groups on galactosaminoglycan chains is to saturate the galactosaminoglycan 
chain binding sites with small pepetide mimetics and this has been successfully demonstrated 
in a mouse model (Skalen, et al., 2002). The rationale underlying this approach can be 
demonstrated by mutating the residues on ApoB100 Thus, as the LDL and PG interaction 
involves clusters of amino acids in the apoB100 that bind to the negatively charged sulfate 
groups on the galactosaminoglycan chain, site A at residues 3148-3158 and site B residues 
3359-3369 (Boren, et al., 1998; Olsson, et al., 1997). Site A in apoB100 becomes functional 
and cooperates with site B to increase the PG binding activity in phospholipase A2 modified 
LDL (Flood, et al., 2004). Transgenic mice expressing mutated site B apoB100 at the PG 
binding site fed a hypercholesterolemic diet for 20 weeks displayed significant protection 
from atherosclerotic lesion development as compared to transgenic mice expressing wild-type 
apoB100 under the same conditions (Skalen, et al., 2002)..  
5.2.2 Galactosaminoglycan directed antibodies 
Administration of a chimeric mouse/human monoclonal antibody (mAb) to induce 
responses against galactosaminoglycans has been shown to be effective at preventing the 
progression of atherosclerotic lesions (Víctor Brito, et al., 2012; V. Brito, et al., 2017; L 
Delgado-Roche, et al., 2013; Sarduy, et al., 2017; Soto, et al., 2012). The anti-atherosclerotic 
antibody was based on the chimeric mouse/human immunoglobulin G1 (IgG1) variant of P3 
mAb that recognises glycolylated gangliosides and sulfatides. The ChP3R99 antibody has an 
additional arginine at position 99 displaying a higher reactivity with antigens. The initial 
work to characterise ChP3R99 as an anti-atherogenic antibody shows that it did not have 
direct impact on the oxidized LDL or foam cell formation, however in an in vitro binding 
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assay, ChP3R99 inhibited 70% of LDL binding to CS (Soto, et al., 2012). Pre-treatment with 
the mAb in an atherosclerosis induced rabbit model completely inhibited lesion progression 
and resulted in lower macrophage infiltration (Soto, et al., 2012). ChP3R99 was compared 
with ChP3S98, a mutant variant with lower reactivity to the antigen in a murine model of 
atherosclerosis fed a hypercholesteraemic diet (Víctor Brito, et al., 2012). Multiple 
administration of ChP3R99 at biweekly or weekly intervals prevented lesion formation in 
apoE-/- mice as compared to treatment with ChP3S98 which had no apparent reduction in 
aortic lesion formation (Víctor Brito, et al., 2012). This can be explained with ChP3S98’s 
lower capacity to generate antibody response against galactosaminoglycans. Pre and post 
immunization of ChP3R99 in apoE-/- induced galactosaminoglycan antibody production as 
compared to the low reactive mAb (Víctor Brito, et al., 2012). 
In 2017, two major studies in this area were published (V. Brito, et al., 2017; Sarduy, et 
al., 2017). Earlier work with the anti-galactosaminoglycan antibodies was in young and 
adolescent apoE-/- male mice (Víctor Brito, et al., 2012). However as age and sex are major 
risk factors in the development of atherosclerosis, Vazquez et al. (Sarduy, et al., 2017) asses 
the influence of these variable on the capacity of the ChP3R99 mAb to generate anti-
galactosaminoglycan response. Immunization with ChP3R99 mAb reduced the mean aortic 
lesion area by 31% and 38% in male and female mice, respectively compared with their 
respective control-treated groups and to 31% in middle aged female mice with spontaneous 
lesions (Sarduy, et al., 2017). Thus neither of the two major risk factors had an impact on the 
anti-galactosaminoglycan properties induced by immunization with this mAb. In the latter 
study the ChP3R99 mAb was used in established atherosclerosis in apoE-/- mice. 
Atherosclerosis was allowed to develop for 11 weeks with apoE-/- mice fed a high fat diet 
followed by subcutaneous injections of ChR3R99 mAb (Sarduy, et al., 2017), atherosclerotic 
lesion progression was reduced by 88% as compared to the control treated group. 
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Collectively these studies define the use of an anti-galactosaminoglycan antibody for the 
prevention of lesion development and as a treatment to halt lesion progression in advanced 
atherosclerosis (Víctor Brito, et al., 2012; V. Brito, et al., 2017; L Delgado-Roche, et al., 
2013; Sarduy, et al., 2017; Soto, et al., 2012). Both of the above strategies are valid 
approaches but are not easily converted into a small chemical entity suitable for long term 
therapy in humans as is required for the treatment of a chronic disease such as atherosclerosis 
for the prevention of CVDs. Nevertheless, there are emerging pharmaceutical delivery 
techniques being developed, so a therapeutic agent is possible and as above such a drug 
would be used in combination with a statin for a two pronged attack on the development of 
this life threatening disease. 
5.3 Targeting the changes in PGs in the vessel wall  
With the position of statins as the drug of first choice for the prevention of 
atherosclerosis, new therapeutic modalities must include the ability to lower cardiovascular 
risk on top of a statin such that dual therapy would be indicated. It is necessary to have a 
mechanism which is different from cholesterol lowering and most likely a vessel wall 
directed therapy addressing the disease process directly. The working hypothesis in the area 
of targeting galactosaminoglycan chain synthesis in that a statin would lower blood 
cholesterol and a “PG (galactosaminoglycan) inhibitor” would reduce the “stickiness” of the 
vessel wall. Proof of concept for this approach has been provided in two studies with imatinib 
(Ballinger, et al., 2010; Getachew, Ballinger, Burch, Reid, et al., 2010). Imatinib was 
developed as a tyrosine kinase Abl inhibitor for the treatment of Chronic Myeloid 
Leukaemia. Imatinib inhibits a very small number of tyrosine kinases including in the current 
context PDGF receptor tyrosine kinase (Getachew, Ballinger, Burch, Reid, et al., 2010). 
Treatment with imatinib results in the inhibition of PDGF stimulated radiosulfate 
incorporation into PGs, elongation of galactosaminoglycan chain and reduced xyloside 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 25 / 46 14/02/2018 
binding to LDL (Ballinger, et al., 2010; Getachew, Ballinger, Burch, Reid, et al., 2010). 
Furthermore, in an in vivo model of atherogenesis, high-fat fed apoE-/- mice, imatinib 
reduced lipid deposition in the vessel wall (Ballinger, et al., 2010). The action of imatinib to 
reduce cholesterol deposition in the vessel wall, occurred without any effect on circulating 
lipid levels in the mice.  
The optimum target in this area is the signalling pathways that controls the synthesis 
of galactosaminoglycan chians on biglycan (Ballinger, et al., 2009; Burch, Ballinger, et al., 
2010; Burch, et al., 2013; Burch, Yang, et al., 2010; Little, et al., 2013; Rostam, et al., 2016; 
Yang, et al., 2010). The actual enzymes which mediate galactosaminoglycan elongation 
(Izumikawa, et al., 2012; Izumikawa, et al., 2011) are not targets themselves because those 
enzymes will be involved in multiple physiological processes and undoubtedly unwanted side 
effects would arise from targeting those enzymes. Furthermore, lipoprotein metabolism is 
very important in organs such as the liver and targeting those enzymes directly might perturb 
endogenous lipoprotein metabolism but targeting the signalling pathways is likely to be 
VSMC specific. In this review we have described in detail signalling pathways which 
mediate galactosaminoglycan hyperelongation in VSMCs and thus present as potential 
therapeutic targets (Burch, Ballinger, et al., 2010; Burch, et al., 2013; Burch, Yang, et al., 
2010; Kamato, et al., 2016; Rostam, et al., 2016).   
6. Conclusions 
Therapies for atherosclerosis have thus far targeted blood borne risk factors and blood 
pressure. Although this has produced some of the most efficacious cardiovascular therapies, 
specifically the cholesterol-lowering statins, there remains a large burden of potentially 
preventable atherosclerosis-related ischemic CVDs. An additional target is the disease 
process in the vessel wall, an area which had been extensively researched over the past three 
decades. There are practical and regulatory limitations in clinical studies based on vascular 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 26 / 46 14/02/2018 
wall directed therapies but it is possible that great advances in imaging technologies may 
open up this area in a way that allows for the development of new classes of agents. Of the 
major areas of vascular wall directed therapies, this review proposes that a prime target is the 
potentially vascular-specific signalling pathways of vasoactive agonists that lead to an 
increase in the “stickiness” of vascular wall PGs for apolipoproteins on atherogenic LDL. 
The two critical processes of lipid retention and inflammation (represented by macrophage 
infiltration and foam cell formation) may pathologically be in series or parallel. Thus, if the 
processes are in series then slowing or preventing lipid retention will disrupt the 
atherosclerotic cascade. Hence, the combination of a statin to reduce blood cholesterol and an 
inhibitor of galactosaminoglycan hyperelongation aimed at stopping LDL accumulation in 
the vessel wall represents a potential strategy for attaining the requisite quantum increase in 
efficacy required to prevent atherosclerosis and thus the burden of CVDs.       
Acknowledgements 
Funding supporting the studies in our laboratory and referenced in this review has been 
received from the National Health and Medical Research Council of Australia, National 
Heart Foundation of Australia, Diabetes Australia Research Trust, academic support 
packages from RMIT University (PJL) and the University of Queensland (PJL) and 
Australian Government scholarships to post-graduate students, Malaysian Government 
Scholarship (MAR). We thank Professor Thomas N. Wight and his laboartory colleagues for 
introducing us to this area.  
Conflict of Interests 
Nothing to declare 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 27 / 46 14/02/2018 
Figures 
Fig 1. Scematic representation of the role of enzymes in galactosaminoglycan 
biosynthesis and modification: Galactosaminoglycan linkage region is made up of 
xylose-galactose-galactose-glucuronic acid (Xyl-Gal-Gal-GlcA). The xylosyltransferase-1 
(XT-1) enzyme  transfers a Xyl to serine (Ser) residue of PG core protein. Two Gal residues 
are added by the action of two enzymes, β-1,3-galactosyl transferase-1 (GalT-1) and GalT-2. 
The β-1,3-glucuronosyl transferase-1 (GlcAT-1) adds a GlcA residues to complete the 
linkage region. Six chondroitin synthase enzymes including chondroitin synthase-1 (ChSy-1), 
ChSy-2, ChSy-3, chondroitin polymerizing factor (ChPF), chondroitin 
N-acetylgalactosaminyltransferase-1 (ChGn-1) and ChGn-2 catalyse subsequent addition of 
repeating disaccharide unit (GalNAc-GlcA) in CS chain. The modification of this precursor 
chondroitin backbone is occur by sulfation with the action of sulfotransferase enzymes 
including uronosyl 2-O-sulfotranferase (UST), chondroitin 4-O-sulfotranferase (C4ST), 
chondroitin 6-O-sulfotranferase (C6ST). Dermatan sulfate-glucoronyl C5-epimerase (DSE) 
enzyme catalyse epimerization at fifth carbon (C-5) position of GlcA in precursor chondroitin 
backbone to synthesize  dermatan backbone. The dermatan backbone is then matured and 
modified by action of another set of sulfotransferases including UST and dermatan 
4-O-sulfotranferase (D4ST). N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase 
(GalNAc4S-6ST) transfers sulfate to C-6 position of N-acetylgalactosamino 4-sulfate 
(GalNac(4SO4)) in both growing CS and DS chain. 
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Fig 2. Platelet derived growth factor (PDGF) mediated signalling pathway leading to 
galactosaminoglycan genes expression: PDGF binding to the PDGF receptor β (PDGFRβ) 
induce receptor dimerization and autophosphorylation on Tyr
857
. Tyr
857 
Phosphorylation 
initiates autophosphorylation of downstream tyrosine residues within the cytoplasmic region 
of the receptor. Adaptor molecules such as Grb and Shc contain SH2 domain that can bind 
these tyrosine kinase docking sites on PDGFR. These adaptor molecules form complex with 
son of sevenless (Sos), a guanine nucleotide exchange factor. Sos mediate the exchange for 
GDP bound to inactive Ras to GTP and activates Ras. Subsequent activation of  Raf leading 
to phosphorylation and activation of mitogen activated protein kinase (MAPK) Erk kinase 
(MEK). Activated MEK sequentially  phosphorylates and  activates extracellular 
signal-regulated kinase 1/2 (Erk1/2). Sp1 transcription factor is  phosphorylated on 
threonine
453
 (Thr
453
) by Erk1/2 and induces expression of galactosaminoglycan synthesizing 
enzymes GlcAT-1 and ChSy-1. 
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Fig 3. Transforming growth factor-β (TGF-β) mediated signalling pathway leading to 
galactosaminoglycan genes expression: Ligand binding induces TGF-β receptor 1 
(TGFBR1) and TGFBR2 dimers to form heterotetrameric complex followed by the activation 
of TGFBR1. TGFBR1 can induce the activation of multiple Ser/Thr kinases. Individual 
Smad2 linker region sites can be specifically phosphorylated by these serine/threonine 
kinases. Phosphorylation of three Ser residues on Ser
245
, Ser
250 
and Ser
255
 leading to induce 
the mRNA expression of two crucial galactosaminoglycan synthesizing enzyme ChSy-1 and 
C4ST-1. Thr
220 
phosphorylation is associated with expression of galactosaminoglycan chain 
initiating enzyme XT-1. These indicates that phosphorylation on one of the three Ser residues 
play key role in galactosaminoglycan chain elongation. In contrast, threonine
220
 (Thr
220
)
 
phosphorylation  plays critical role in initiation of galactosaminoglycan chain in TGF-β 
stimulated galactosaminoglycan synthesis. 
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Fig 4. G-protein coupled receptor (GPCR) transactivation of PTKR and S/TKR leading 
to galactosaminoglycan gene expression: Thrombin mediated galactosaminoglycan  chain 
elongation does not involve classical GPCR signalling rather it utilizes transactivation 
pathways for both PTKR and S/TKR to elicit response. GPCR transactivation of PTKR 
involve matrix metalloproteinases (MMPs), but S/TKR does not. Activated S/TKRs can 
directly phosphorylate transcriptiom factor Smad2 on its carboxy terminal. S/TKRs also 
phosphorylates the linker region of Smad2 via serine/threonine kinases (Ser/Thr kinases). 
Combined speculation of different studies also provide an indication to the Smad2 linker 
region phosphorylation by PTKRs. Smad2 linker region phosphorylation can induce the 
expression of galactosaminoglycan synthesizing enzymes XT-1, ChSy-1 and C4ST-1.  
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